

	page		page
Oncology and emesis	09,52,64	Sales	
Operating and financial review and prospects	47–68	Consumer Healthcare	09,54,65,150
Oral care	09,54,65,150	Pharmaceuticals	08–09,12,49–53, 62–65,146–149,150
Other operating income/(expense)	55,66,89	SB Clinical laboratories	104,105,106
Outlook	03,57,58	Segment information	86–88,150
Over-the-counter (OTC) medicines	09,54,65,150	Selected financial data	67
		Senior management – compensation and interests	46
Patents	22,23	Share capital	100,158
Payment policies	59	Share premium account	100
Pension and other post-retirement benefits	79,116–117,133–135	Share price	155,157,158
Pipeline	16–19	Share purchases	61
Post balance sheet events	78	Share statistics	151
Presentation of financial statements	78	Shareholder information	33,157
Price controls	11	Shareholder return	02,154–155
Principal financial statements in US\$	142–143	Shareholders' funds	59
Products		Shareholdings – analysis	159
approvals and submissions	14	Statement of total recognised gains and losses	72–73,84–85
Consumer Healthcare	09,10–11,21,23,65	Strategic Master Plan	13
delivered to market	15		
development pipeline	16–19	Taxation	56,66,80,90–91,154
discontinuations	15	Taxation information for shareholders	156
liability	103	Tax rate	48,91
new product development	21	Trade marks	05,07,23
new product supply	21	Treasury operations	34,60
Pharmaceuticals	02,07–09,10–14,22–23, 49–53,62–65,146–150	Treasury policies	60
Profit and loss account	48,67,72–73,84–85	Tuberculosis	26
Property, plant and equipment	24		
Provisions for liabilities and charges	59,97	UK segment	132
		US GAAP – reconciliation to US accounting principles	120–135
Reconciliation of movements in equity shareholders' funds	76	consolidated balance sheet	121
Registrar	157	consolidated income statement	122–123
Regulation	11	comprehensive income and changes in shareholders' equity	122–123
Remuneration & Nominations Committee	30,32,38	consolidated statement of cash flows	124,129
Remuneration report	37–46	earnings per share/ADS	122–123,130
Report of the Directors	02–68	material differences between UK and US GAAP	125–129
Research and development		post-retirement benefits	133–135
accounting policy	79	purchase accounting	120,126–127
animals and research	21	results under US accounting principles	68
Consumer Healthcare	21	segment information	131–132
diseases of the developing world	28	selected financial data	67
expenditure	48,54,66	taxation	130
Pharmaceuticals	14	US\$ – convenience translation of principal financial statements	142–143
pipeline	16–19		
Respiratory	08,10,50,62	Vaccines	09,10,52,64
Return on capital employed	151		
Revenue – accounting policy	79	World economy	49
Risk factors	57,161	World market	49
Risk Oversight and Compliance Council (ROCC)	34		

---

O

S

P

T

R

U

V

W